

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
APPLICATIONIn re PATENT APPLICATION of
Inventor(s): MATSUI et al.Appln No.: 07 / 308,282
series code ↑ ↑ serial no.

Filed: February 9, 1989

Title: TYPE a PLATELET-DERIVED GROWTH
FACTOR RECEPTOR GENEHon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

R E S P O N S E
RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is to be treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

* Query: Is appeal *
* deadline now? If *
* so, file Notice of *
* Appeal separately *

Claims
remaining
after
amendment

Highest
number
previously
paid for

Present
Extra

				GROUP	6 NOV 6 20	20 FEE
1. Total Effective Claims	* 15	minus ** 15	= 0	X \$20.00	PH \$ -0-	
2. Independent Claims	* 4	minus *** 4	= 0	X \$60.00	PH \$ -0-	
3. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave <u>blank</u> if this is a <u>reissue</u> appln) add \$200.00					30	+ -0-
4. <u>Original</u> due date: [] None; [X] (date) August 24, 1990						
5. Petition is hereby made to extend the <u>original</u> due date to cover the date this response is filed for which the requisite fee is attached (1 month \$100; 2 months \$300; 3 months \$730):						+ 730.00
6. If <u>Terminal Disclaimer</u> attached, add Rule 20(d) Official fee (\$100)						+ -0-
7.					Subtotal \$	730.00
8. If "small entity" verified statement filed [] previously, [] herewith, enter one-half (1/2) of subtotal					Subtract -	-0-
9.					Subtotal \$	730.00
10. Enter any previous extension fee <u>paid</u> since above <u>original</u> due date (item 4) and subtract -						-0-
11.					TOTAL FEE ATTACHED \$	730.00

12. *If the entry in this space is less than entry in the next space, the "Present Extra" result is "0".

13. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

14. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed

100 KB 11/27/90 07308282

1 117 730.00 CK

1615 L Street N.W.
Eleventh Floor
Washington, D.C. 20036-5601
Tel: 861-3000
Atty/Sec: WTS:KIK/tlc

CUSHMAN, DARBY & CUSHMAN
By Atty: Watson T. Scott

Sig: *Benjamin L. Scott* 16773

Reg. No. 26,581

Fax: (202) 822-0944

Tel.: (202) 3067

CDC-120 11/90 NOTE: File this cover sheet in duplicate with post card receipt (CDC-103)
and attachments

ID	MCH	TPE	NAME OR ACCOUNT	C-NBR	MLEDTE	CURDTE	F-C	\$ AMOUNT
C	100	1	07308282	00060	901115	901127	117	730.00

NO MORE TRANSACTIONS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

18C

7-24-90 Washington

In re Application of
MATSUI et al.

Serial No: 07/308,282

Examiner: Marschela, A.

Filed: February 9, 1989

Group Art Unit: 187

For: TYPE α PLATELET-DERIVED
GROWTH FACTOR RECEPTOR GENE

* * * * *

November 5, 1990

RECEIVED

90 NOV -6 PM 1:12

GROUP 180

RESTRICTION REQUIREMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:


In response to the Restriction Requirement of July 24, 1990, applicants' elect Group I drawn to the alpha-PDGF receptor gene and its expression in prosecuting this application. Non-elected claims will be cancelled in due course while reserving the right to file a divisional application covering same.

The Examiner required restriction between the antibodies to PDGF receptor proteins (Group II) and immunoassay

U. S. Application of MATSUI et al.
Serial No. 07/308,282
Page 2

methods utilizing these antibodies (Group IV). In future filed divisional applications covering the claim, applicants' make their intention to traverse between the antibodies and antibody immunoassays.

Respectfully submitted,
CUSHMAN, DARBY & CUSHMAN

By 
Watson T. Scott #18681
Reg. No. 26,581
202-861-3067

WTS:KIK/tlc

1615 L Street, N.W.
Suite 1100
Washington, D.C. 20036-5601
Tel: (202) 861-3000